Advertisement

Racial Differences in S100b Levels in Persons with Schizophrenia

  • Jessica M. GannonEmail author
  • Deanna L. Kelly
  • Abigail Besch
  • Tanu Thakur
  • Neil Khurana
  • Michael R. Shurin
  • Galina V. Shurin
  • Jaspreet S. Brar
  • Daniela Cihakova
  • Monica V. Talor
  • K. N. Roy Chengappa
Original Paper

Abstract

The calcium-binding protein S100b is secreted by glial cells in the brain and is also expressed by melanocytes. In nanomolar concentrations, S100b is considered to be a neurotrophic factor, but in micromolar concentrations, it is thought to reflect CNS injury and inflammation. Seen as a potential biomarker in traumatic brain injury, meta-analytic data from several studies report that S100b levels are significantly higher in persons with long standing schizophrenia, but also among first-episode patients compared to healthy control subjects. However, ethnic or racial differences are typically not mentioned when reporting levels of S100b. We assessed serum S100b levels in persons with schizophrenia (n = 136) who were participants in two independent research studies using the same enzyme-linked immunoassay (ELISA). African-American subjects had significantly higher levels of S100b (41.9 pg/ml ± 62.2) than Caucasian subjects (24.9 pg/ml ± 45.4) in the combined dataset (Mann-Whitney U = 1307, p < 0.001), as well as in each independent study. There were no significant differences in S100b levels between men and women. No significant correlations were observed between S100b levels and demographic or clinical variables. These data suggest that ethnicity or race should be given serious consideration when studying and interpreting S100b levels in persons with schizophrenia.

Keywords

Schizophrenia S100b African-American Caucasian Inflammation Race 

Notes

Acknowledgements

The authors gratefully acknowledge Patricia Schlicht, RN, MA, who was the Research Nurse Coordinator for Study 1, and Joan Spinogatti, who handled IRB submission for Study 1, and coordinated author collaboration and drafts of the manuscript, including creating the figures and tables. We also thank Fang Liu who helped with data management, William W. Eaton, PhD, Nicola Cascella, MD and Alessio Fasano, MD who all helped with the study design for study 2.

Funding Information

Study 1 was funded by an award to K. N. Roy Chengappa (PI) by the Stanley Medical Research Institute, and Study 2 was funded by pilot funding from the Maryland Psychiatric Research Center to Deanna Kelly (PI).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. 2017;159(2):209–25.CrossRefGoogle Scholar
  2. 2.
    Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res. 2007;85(7):1373–80.CrossRefGoogle Scholar
  3. 3.
    Schümberg K, Polyakova M, Steiner J, Schroeter ML. Serum S100B is related to illness duration and clinical symptoms in schizophrenia-a meta-regression analysis. Front Cell Neurosci. 2016;10:46.CrossRefGoogle Scholar
  4. 4.
    Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(2):361–4.CrossRefGoogle Scholar
  5. 5.
    Steiner J, Bielau H, Bernsteinc HG, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry. 2006;77(11):1284–7.CrossRefGoogle Scholar
  6. 6.
    Rothermundt M, Ahn JN, Jörgens S. S100B in schizophrenia: an update. Gen Physiol Biophys. 2009; 28 Focus Issue:F76–81.Google Scholar
  7. 7.
    Steiner J, Myint A M, Schiltz K, Westphal S, Bernstein HG, Walter M, et al. S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc. Psychiatry Neurol. 2010:480707.  https://doi.org/10.1155/2010/480707 CrossRefGoogle Scholar
  8. 8.
    Milleit B, Smesny S, Rothermundt M, Preul C, Schroeter ML, et al. Serum S100B protein is specifically related to white matter changes in schizophrenia. Front Cell Neurosci. 2016;10:33.CrossRefGoogle Scholar
  9. 9.
    van Engelen BG, Lamers KJ, Gabreels FJ, Wevers RA, van Geel WJ, Borm GF. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 1992;38:813–6.PubMedGoogle Scholar
  10. 10.
    Nygaard O, Langbakk B, Romner B. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder. Clin Chem. 1997;43:541–3.PubMedGoogle Scholar
  11. 11.
    Abdesselam BO, Vally J, Adem C, Foglietti MJ, Beaudeux JL. Reference values for serum S100B protein depend on the race of individuals. Clin Chem. 2003;49:836–7.CrossRefGoogle Scholar
  12. 12.
    Asken BM, Bauer RM, DeKosky ST, Houck ZM, Moreno CC, Jaffee MS, et al. Concussion biomarkers assessed in collegiate student-athletes (BASICS) I: normative study. Neurology. 2018;91(23):e2109–22.CrossRefGoogle Scholar
  13. 13.
    Morera-Fumero AL, Dias-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez MR. Day/night changes in S100b protein concentrations in acute paranoid schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;75:207–12.CrossRefGoogle Scholar
  14. 14.
    Chengappa KNR, Brar JS, Gannon JM, Schlicht PJ. Adjunctive use of a standardized extract of Withania somnifera (Ashwagandha) to treat symptom exacerbation in Schizophrenia: A Randomized, Double-blind, Placebo-controlled study. J Clin Psychiatry. 2018;79(5):17m11826.CrossRefGoogle Scholar
  15. 15.
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.CrossRefGoogle Scholar
  16. 16.
    Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42:S90–4.CrossRefGoogle Scholar
  17. 17.
    Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman S, et al. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res. 2012;140(1–3):262–3.CrossRefGoogle Scholar
  18. 18.
    Deng H, Kahlon RS, Mohite S, Amin PA, Zunta-Soares G, Colpo GD, et al. Elevated plasma S100B, psychotic symptoms, and cognition in schizophrenia. Psychiatry Q. 2018;89:53–60.CrossRefGoogle Scholar
  19. 19.
    O’Connell K, Thakore J, Dev KK. Levels of S100b are raised in female patients with schizophrenia. BMC Psychiatry. 2013;13:146.CrossRefGoogle Scholar
  20. 20.
    Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in intergroup trial ECOG 1694. J Clin Oncol. 2009;27(1):38–44.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jessica M. Gannon
    • 1
    • 2
    Email author
  • Deanna L. Kelly
    • 3
  • Abigail Besch
    • 1
    • 2
  • Tanu Thakur
    • 4
  • Neil Khurana
    • 5
  • Michael R. Shurin
    • 6
  • Galina V. Shurin
    • 6
  • Jaspreet S. Brar
    • 1
  • Daniela Cihakova
    • 7
  • Monica V. Talor
    • 7
  • K. N. Roy Chengappa
    • 1
    • 2
  1. 1.Western Psychiatric HospitalUniversity of Pittsburgh Medical CenterPittsburghUSA
  2. 2.School of MedicineUniversity of PittsburghPittsburghUSA
  3. 3.Maryland Psychiatric Research CenterUniversity of Maryland, School of MedicineBaltimoreUSA
  4. 4.Institute of Human Behavior and Allied SciencesNew DelhiIndia
  5. 5.University of Pittsburgh Medical CenterPittsburghUSA
  6. 6.Department of PathologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  7. 7.Department of Pathology, School of MedicineJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations